Type 1 interferon deficiency: Biomarker of patients at risk of severe COVID

(INSERM (Institut national de la santé et de la recherche médicale)) Which patients are more likely to develop a severe form of Covid-19? This is a key question that needs to be answered to improve the individual management and prognosis of patients. In a study published in Science on July 13, teams from AP-HP, Inserm, Université of Paris, Institut Pasteur and Institut Imagine describe a unique and unexpected immunological phenotype in severe and critical patients.